Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

733 ARTÍCULOS , VIENDO DEL 571 AL 585

Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer's disease

Iwata A, Sakata Y, Koizumi K, Endo A, Kuang W, Sumitomo K, Ishii M.

J Prev Alzheimers Dis. 2026 May;13(5):100541. doi: 10.1016/j.tjpad.2026.100541. Epub 2026 Mar 17.

Effects of different dietary restriction regimens on cognitive function and pathological markers in Alzheimer's disease mouse models: A systematic review and meta-analysis

Sun L, Xu X, Wang Z, Meng Y, Li Y, Hou Y, Gao X, Cui H, Li Y.

Neurosci Biobehav Rev. 2026 May;184:106601. doi: 10.1016/j.neubiorev.2026.106601. Epub 2026 Feb 8.

Lecanemab appropriate use recommendations for clinical practice in the UK

Mummery CJ, Rasmussen J, Blackburn D, Coulthard E, Davies RR, Dorsey R, Fox NC, Hosseini AA, Ivenso C, Jones M, Kennelly SP, Kipps C, Lashley D, Mackay G, Negi R, Nilforooshan R, Passmore PA, Perry R, Raymont V, Rowe JB, Russ TC, Taylor JP, Burns A.

J Neurol Neurosurg Psychiatry. 2026 Apr 15;97(5):372-384. doi: 10.1136/jnnp-2025-336597.

The interventional effect of acupuncture on overall cognitive function in Alzheimer's disease spectrum disorders: A meta-analysis

Chen Y, Zhao S, Yang F, Wang Y, Han Z, Han F, Wang Z, Chen Z, Sun K, Liang P, Li K.

J Alzheimers Dis. 2026 Jun;111(3):959-978. doi: 10.1177/13872877261438495. Epub 2026 Apr 8.

Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial

Devanand DP, Wisniewski T, Razlighi Q, Qian M, Wei R, Andrews HF, Acosta EP, Bell KL, Pelton GH, Deliyannides D, Perrin AC, Caccappolo E, Gershon AA, Prasad KM, Kreisl WC, Mintz A, Huey ED.

JAMA. 2026 Feb 10;335(6):511-522. doi: 10.1001/jama.2025.21738.

The Alzheimer's Pathways Sleep Study (ALPS): an experimental randomized controlled trial to improve cognition and Alzheimer's pathophysiology through slow-wave sleep

Dong YC, Habte RF, Dessa KM, Fletcher ME, Ianni AM, Lopresti BJ, Aizenstein HJ, Cohen AD, Karikari TK, Weinstein AM, Gebara MA, Wallace ML, Buysse DJ, Wilckens KA.

Trials. 2026 Feb 19;27(1):237. doi: 10.1186/s13063-026-09505-w.

Redefining management of mild cognitive impairment and Alzheimer's disease through the shift from clinical to clinical-biological diagnosis: Insights from a single-center experience

Giuffrè GM, Battisti F, Tudor AM, Lenkowicz J, Avitabile A, Rosati AM, Martellacci N, Patarnello S, Torelli F, Cesario A, Marra C.

J Alzheimers Dis. 2026 Feb;109(4):1945-1954. doi: 10.1177/13872877251411461. Epub 2026 Jan 5.

Precision pathways: optimising amyloid PET for sustainable Alzheimer's disease care

Morbelli SD, Bozzali M, Cagnin A, Cecchin D, Chiti A, Filippi M.

J Neurol. 2026 May 26;273(6):340. doi: 10.1007/s00415-026-13874-2.

The Right Person, the Right Treatment, at the Right Time in Alzheimer's Disease: Insights From the 2025 Brain Aging Symposium

de Magalhães CG, Moldakozhayev A, Lopez MV, Bowman GL, Chhatwal JP, Kellis M, Mohs R, Nisenbaum L, Quiroz YT, Raju RM, Sperling RA, Moqri M, Gladyshev VN.

Aging Cell. 2026 Jan;25(1):e70351. doi: 10.1111/acel.70351.

The role of MicroRNAs in Alzheimer's disease: from pathogenesis to therapeutic potential

Zhou Y, Li S, Xiang J.

Mol Biol Rep. 2026 Mar 31;53(1):558. doi: 10.1007/s11033-026-11746-6.

Tau and β-Amyloid Relevant Pathology as a Central Therapeutic Target in Alzheimer's Disease

Strużyńska L, Adamiak K, Sidoryk-Węgrzynowicz M.

Biomolecules. 2026 Apr 17;16(4):595. doi: 10.3390/biom16040595.

Consensus statement on the use of Alzheimer's disease biomarkers and anti-amyloid therapies in Hong Kong

Shum CK, Shea YF, Au Yeung TW, Chan CCY, Chan WC, Cheng WK, Cheung NYF, Cho DHY, Chow TK, Fong GCY, Ip BYM, Kwok JSH, Lai BMH, Lam LCW, Lee ATC, Lok CM, Mok KY, Ng DKK, Siu DYW, Yeung PY, Tam SKF.

Hong Kong Med J. 2026 Apr;32(2):144-154. doi: 10.12809/hkmj2514198. Epub 2026 Apr 13.

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?

Higgins M, Wasef V, Kwakowsky A.

Int J Mol Sci. 2026 Jan 15;27(2):883. doi: 10.3390/ijms27020883.

Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment

Andreozzi E, Yagi T, Wildsmith K, Rawal S, Horie K, Boyd P, Takahashi E, Barthélemy NR, Aluri J, Charil A, Reilhac A, Gordon BA, Flores S, Verbel D, Sauter N, Benzinger TLS, McDade E, Mummery C; Dominantly Inherited Alzheimer Network (DIAN); Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU); Zhou J, Bateman RJ, Reyderman L.

Alzheimers Res Ther. 2026 Apr 10;18(1):87. doi: 10.1186/s13195-026-02047-y.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias